- Home
- NFBK vs VERV Comparison
NFBK vs VERV Comparison
Compare NFBK & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFBK
- VERV
- Stock Information
- Founded
- NFBK 1887
- VERV 2018
- Country
- NFBK United States
- VERV United States
- Employees
- NFBK N/A
- VERV N/A
- Industry
- NFBK Major Banks
- VERV Medicinal Chemicals and Botanical Products
- Sector
- NFBK Finance
- VERV Health Care
- Exchange
- NFBK Nasdaq
- VERV Nasdaq
- Market Cap
- NFBK 406.5M
- VERV 384.2M
- IPO Year
- NFBK 2007
- VERV 2021
- Fundamental
- Price
- NFBK $12.22
- VERV $11.27
- Analyst Decision
- NFBK Buy
- VERV Buy
- Analyst Count
- NFBK 2
- VERV 10
- Target Price
- NFBK $13.00
- VERV $14.57
- AVG Volume (30 Days)
- NFBK 210.0K
- VERV 8.0M
- Earning Date
- NFBK 07-23-2025
- VERV 08-07-2025
- Dividend Yield
- NFBK 4.26%
- VERV N/A
- EPS Growth
- NFBK 1.58
- VERV N/A
- EPS
- NFBK 0.76
- VERV N/A
- Revenue
- NFBK $128,407,000.00
- VERV $59,613,000.00
- Revenue This Year
- NFBK $12.68
- VERV $27.75
- Revenue Next Year
- NFBK $15.15
- VERV N/A
- P/E Ratio
- NFBK $16.06
- VERV N/A
- Revenue Growth
- NFBK N/A
- VERV 271.44
- 52 Week Low
- NFBK $8.92
- VERV $2.87
- 52 Week High
- NFBK $14.39
- VERV $11.41
- Technical
- Relative Strength Index (RSI)
- NFBK 59.51
- VERV 83.09
- Support Level
- NFBK $11.39
- VERV $11.16
- Resistance Level
- NFBK $12.17
- VERV $11.34
- Average True Range (ATR)
- NFBK 0.39
- VERV 0.20
- MACD
- NFBK 0.02
- VERV 0.06
- Stochastic Oscillator
- NFBK 85.83
- VERV 97.29
About NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.